Children with eczema, antibiotic management study

Not Applicable

Completed

• Conditions: Infected eczema; Skin and Connective Tissue Diseases; Atopic dermatitis

• Registration Number: ISRCTN96705420
• Lead Sponsor: Cardiff University (UK)

Brief Summary

2016 results in: http://www.ncbi.nlm.nih.gov/pubmed/26938214

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-06-27
• Study Completion: 2015-03-25
• Last Update Posted: 26 August 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 510

Inclusion Criteria

Children (aged 3 months to less than five years) with atopic eczema (as defined by UK working party criteria) who are presenting in primary care and their treating clinician suspects infected eczema because of at least one of the following:
The UK working party criteria state that in order to qualify as a case of atopic eczema with the UK diagnostic criteria, the child MUST have:
1. An itch skin condition in the last 12 months
2. And three or more of the following:
2.1. Onset below age 2 (Not used in children under 4 years old)
2.2.History of flexural involvement.
2.3. History of general dry skin atopic disease (In children aged under 4 years old, history of atopic disease in a first degree relative may be included)
2.4. Personal history of other atopic disease
3. The eczema is failing to respond to standard treatment
4. There is a flare in the severity or extent of the eczema
5. There is weeping, crusting, or pustules

Exclusion Criteria

1. Use of oral or topical antibiotics in the past week
2. Use of potent (Betamethasone valerate 0.1%, Betacap, Betesil, Bettamousse, Betnovate, Cutivate, Diprosone, Elocon, Hydrocortisone butyrate, Locoid, Locoid Crelo, Metosyn, Nerisone, Synalar, Aureocort, Betnovate-C, Betnovate-N, Fucibet, Lotriderm, Synalar C, Synalar N, Diprosalic) or very potent (Clarelux, Dermovate, Etrivex, Nerisone Forte, Dermovate-NN) corticosteroids within the past week
3. Immune suppression
4. Features suggestive of eczema herpeticum (significant pain, punched out lesions)
5. Severe infection (systemic upset, cellulitis) ) and/or suspected infection warrants immediate hospitalisation or urgent dermatology referral
6. Severity of eczema
7. Known renal and / or hepatic impairment
8. Allergy to penicillin and erythromycin or allergy to penicillin and contraindication to erythromycin, such as current use of medication that is known to interact with erythromycin
9. Allergy the fusidic acid
10. Current use of any medication that is known to interact with fuscidic acid
11. Extensive eczema (EASI score ? 40 [equates to moderately severe eczema affecting 80% of body surface area])

Study & Design

• Study Type: Interventional
• Study Design: Not specified